Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Neoplasms 2Sarcoma, Kaposi 1Neurofibromatosis 2 1Neurofibromatoses 1Neoplasms by Histologic Type 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1HIV Infections 1AIDS-related Kaposi sarcoma 1

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms × emvododstat × Clear all
NCT03761069 2022-02-02

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

PTC Therapeutics

Phase 1 Terminated
33 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute

NCT00704821 2019-05-10

PTC299 for Treatment of Advanced Cancer

PTC Therapeutics

Phase 1 Terminated
76 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡